FDA Approval Alert: The Need-to-Know | SIR-Sphere Y-90 in Hepatocellular Carcinoma

In July 2025, the FDA approved SIR-Spheres Y-90 resin microspheres as a treatment for patients with hepatocellular carcinoma.

SIR-Sphere Y-90 resin microspheres are the only approved radioembolization treatments in the US for both HCC and mCRC.
FDA Approves SIR-Sphere Y-90 in HCC
Article
Jul 7, 2025 1:47 PM
SIR-Sphere Y-90 resin microspheres are the only approved radioembolization treatments in the US for both HCC and mCRC.